Insmed presents new data on respiratory therapies and supports bronchiectasis diagnosis initiative at ATS 2026.

Insmed announced it will present six abstracts at the American Thoracic Society International Conference 2026, including new data on ARIKAYCE for Mycobacterium avium complex lung disease and BRINSUPRI for non-cystic fibrosis bronchiectasis. The company also shared pharmacokinetic findings on investigational treprostinil palmitil inhalation powder and highlighted disease burden in pulmonary hypertension. Additionally, Insmed is funding a research grant to improve bronchiectasis diagnosis across the U.S., aiming to reduce misdiagnosis and enhance patient care. These efforts underscore Insmed's commitment to advancing treatments for serious respiratory diseases.